Study investigating the efficacy and the safety of the drug named ‘Tazemetostat’ in patients with synovial sarcoma or tumors said to be ‘INI-1 negative’
Goal of this study
To treat synovial sarcoma and tumors said to be ‘INI-1 negative’
Synovial sarcoma is a rare form of cancer which usually occurs near to the joints of the arm, neck or leg. INI-1 negative tumors are a group of rare tumors that include:
- Malignant Rhabdoid Tumors
- Rhabdoid Tumors of the Kidney
- Atypical Teratoid Rhabdoid Tumors
- Selected Tumors With Rhabdoid Features
- Malignant Rhabdoid Tumor of Ovary
- Renal Medullary Carcinoma
- Epithelioid Sarcoma
- Epithelioid malignant peripheral nerve sheath tumor
- Extraskeletal myxoid chondrosarcoma
- Myoepithelial carcinoma
- Other INI1-negative malignant tumors not cited here
This study will investigate the efficacy and the safety of a drug named ‘Tazemetostat’ in treating patients with the forms of cancer described above. ‘Tazemetostat’ will be given to the patient through the mouth twice a day at a dose of 800 mg for 28 days.
Who can participate in this study?
Patients who have been diagnosed with one of the types of cancer described above and who are 16 years and older may be eligible to participate in this study. This study accepts both men and women and does not accept healthy volunteers.
Important: Additional eligibility criteria apply and the patient’s record will be verified by the study doctor (with the patient’s approval) to confirm eligibility.
ClinicalTrials.gov Identifier: NCT02601950
To know if you're eligible to participate in this trial, please fill-up the form below and we will contact you shortly.